Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Total Current Liabilities (2016 - 2025)

Traws Pharma (TRAW) has disclosed Total Current Liabilities for 14 consecutive years, with $7.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities fell 5.52% to $7.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.9 million, a 5.52% decrease, with the full-year FY2024 number at $11.5 million, up 25.09% from a year prior.
  • Total Current Liabilities was $7.9 million for Q3 2025 at Traws Pharma, up from $7.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $11.5 million in Q4 2024 to a low of $5.9 million in Q1 2022.
  • A 5-year average of $8.3 million and a median of $8.0 million in 2022 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: crashed 38.98% in 2021, then surged 55.08% in 2023.
  • Traws Pharma's Total Current Liabilities stood at $6.1 million in 2021, then skyrocketed by 31.58% to $8.0 million in 2022, then grew by 14.59% to $9.2 million in 2023, then rose by 25.09% to $11.5 million in 2024, then crashed by 31.61% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Total Current Liabilities are $7.9 million (Q3 2025), $7.4 million (Q2 2025), and $10.4 million (Q1 2025).